Literature DB >> 12525995

Molecular and cellular basis of pulmonary vascular remodeling in pulmonary hypertension.

T K Jeffery1, N W Morrell.   

Abstract

Clinical pulmonary hypertension is characterized by a sustained elevation in pulmonary arterial pressure. Pulmonary vascular remodeling involves structural changes in the normal architecture of the walls of pulmonary arteries. The process of vascular remodeling can occur as a primary response to injury, or stimulus such as hypoxia, within the resistance vessels of the lung. Alternatively, the changes seen in more proximal vessels may arise secondary to a sustained increase in intravascular pressure. To withstand the chronic increase in intraluminal pressure, the vessel wall becomes thickened and stronger. This "armouring" of the vessel wall with extra-smooth muscle and extracellular matrix leads to a decrease in lumen diameter and reduced capacity for vasodilatation. This maladaptive response results in increased pulmonary vascular resistance and consequently, sustained pulmonary hypertension. The process of pulmonary vascular remodeling involves all layers of the vessel wall and is complicated by the finding that cellular heterogeneity exists within the traditional compartments of the vascular wall: intima, media, and adventitia. In addition, the developmental stage of the organism greatly modifies the response of the pulmonary circulation to injury. This review focuses on the latest advances in our knowledge of these processes as they relate to specific forms of pulmonary hypertension and particularly in the light of recent genetic studies that have identified specific pathways involved in the pathogenesis of severe pulmonary hypertension. Copyright 2002, Elsevier Science (USA). All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12525995     DOI: 10.1053/pcad.2002.130041

Source DB:  PubMed          Journal:  Prog Cardiovasc Dis        ISSN: 0033-0620            Impact factor:   8.194


  82 in total

Review 1.  PPARgamma as a potential therapeutic target in pulmonary hypertension.

Authors:  Roy L Sutliff; Bum-Yong Kang; C Michael Hart
Journal:  Ther Adv Respir Dis       Date:  2010-06       Impact factor: 4.031

Review 2.  MicroRNA and vascular remodelling in acute vascular injury and pulmonary vascular remodelling.

Authors:  Robert A McDonald; Akiko Hata; Margaret R MacLean; Nicholas W Morrell; Andrew H Baker
Journal:  Cardiovasc Res       Date:  2011-11-07       Impact factor: 10.787

3.  Alterations of cellular bioenergetics in pulmonary artery endothelial cells.

Authors:  Weiling Xu; Thomas Koeck; Abigail R Lara; Donald Neumann; Frank P DiFilippo; Michelle Koo; Allison J Janocha; Fares A Masri; Alejandro C Arroliga; Constance Jennings; Raed A Dweik; Rubin M Tuder; Dennis J Stuehr; Serpil C Erzurum
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-16       Impact factor: 11.205

4.  Hypoxia-induced pulmonary vascular remodeling requires recruitment of circulating mesenchymal precursors of a monocyte/macrophage lineage.

Authors:  Maria G Frid; Jacqueline A Brunetti; Danielle L Burke; Todd C Carpenter; Neil J Davie; John T Reeves; Mark T Roedersheimer; Nico van Rooijen; Kurt R Stenmark
Journal:  Am J Pathol       Date:  2006-02       Impact factor: 4.307

5.  Metabolism and Redox in Pulmonary Vascular Physiology and Pathophysiology.

Authors:  Norah Alruwaili; Sharath Kandhi; Dong Sun; Michael S Wolin
Journal:  Antioxid Redox Signal       Date:  2018-12-21       Impact factor: 8.401

6.  Pharmacologic agents elevating cAMP prevent arginase II expression and proliferation of pulmonary artery smooth muscle cells.

Authors:  Bernadette Chen; Andrea E Calvert; Xiaomei Meng; Leif D Nelin
Journal:  Am J Respir Cell Mol Biol       Date:  2012-03-23       Impact factor: 6.914

7.  SM22alpha-targeted deletion of bone morphogenetic protein receptor 1A in mice impairs cardiac and vascular development, and influences organogenesis.

Authors:  Nesrine El-Bizri; Christophe Guignabert; Lingli Wang; Alexander Cheng; Kryn Stankunas; Ching-Pin Chang; Yuji Mishina; Marlene Rabinovitch
Journal:  Development       Date:  2008-07-30       Impact factor: 6.868

Review 8.  Pathogenic mechanisms of pulmonary arterial hypertension.

Authors:  Stephen Y Chan; Joseph Loscalzo
Journal:  J Mol Cell Cardiol       Date:  2007-09-20       Impact factor: 5.000

9.  Urotensin II-induced signaling involved in proliferation of vascular smooth muscle cells.

Authors:  Myriam Iglewski; Stephen R Grant
Journal:  Vasc Health Risk Manag       Date:  2010-09-07

10.  Mechanics and Function of the Pulmonary Vasculature: Implications for Pulmonary Vascular Disease and Right Ventricular Function.

Authors:  Steven Lammers; Devon Scott; Kendall Hunter; Wei Tan; Robin Shandas; Kurt R Stenmark
Journal:  Compr Physiol       Date:  2012-01-01       Impact factor: 9.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.